{
  "id": "56bf365eef6e39474100000e",
  "type": "yesno",
  "question": "Do mutations of AKT1 occur in meningiomas?",
  "ideal_answer": "Yes, AKT1 mutation occurs in meningiomas.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25146167",
    "http://www.ncbi.nlm.nih.gov/pubmed/23475883",
    "http://www.ncbi.nlm.nih.gov/pubmed/23348505",
    "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
    "http://www.ncbi.nlm.nih.gov/pubmed/24096618",
    "http://www.ncbi.nlm.nih.gov/pubmed/25857641"
  ],
  "snippets": [
    {
      "text": "The recent identification of somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25857641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A mutation in PIK3CA or AKT1 was found in around 9 % of the cases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25146167",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24096618",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AKT1E17K mutations were exclusively seen in meningiomas and occurred in 65 of 958 of these tumors. A strong preponderance was seen in the variant of meningothelial meningioma WHO grade I of basal and spinal localization. In contrast, AKT1E17K mutations were rare in WHO grade II and absent in WHO grade III meningiomas. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24096618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We observed strong up-regulation of SFRP1 expression in all meningiomas with AKT1E17K mutation and in HEK293 cells after transfection with mutant AKT1E17K, but not in meningiomas and HEK293 cells lacking this mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24096618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SMO and AKT1 mutations occur in non-NF2 meningiomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475883",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recurrent mutations in SMO and AKT1 are mutually exclusive with NF2 loss in meningioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475883",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348505",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SMO and AKT1 mutations occur in non-NF2 meningiomas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475883",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The recent identification of somatic mutations in components of the SHH-GLI1 and AKT1-MTOR signaling pathways indicates the potential for cross talk of these pathways in the development of meningiomas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25857641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23348505",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Recurrent mutations in SMO and AKT1 are mutually exclusive with NF2 loss in meningioma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23475883",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways. These mutations were present in therapeutically challenging tumors of the skull base and higher grade. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A subset of meningiomas lacking NF2 alterations harbored recurrent oncogenic mutations in AKT1 (p.Glu17Lys) and SMO (p.Trp535Leu) and exhibited immunohistochemical evidence of activation of these pathways. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23334667",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "http://www.biosemantics.org/jochem#4264173",
    "http://www.disease-ontology.org/api/metadata/DOID:3565",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154",
    "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008579"
  ],
  "exact_answer": "Yes"
}